购物车
- 全部删除
- 您的购物车当前为空
Ulodesine(又名BCX4208)是一种嘌呤核苷酸磷酸化酶(PNP)抑制剂,目前正由Biocryst公司开发,旨在治疗痛风,计划作为每日一次的口服长期治疗方案。Ulodesine通过作用于嘌呤代谢途径中黄嘌呤氧化酶上游,来减少血清尿酸(sUA)的产生。其对PNP的半抑制浓度(IC(50))为0.5 nM。目前,BCX-4208还在早期临床试验阶段,用于探索其在银屑病和痛风治疗中的潜在效益。
Ulodesine(又名BCX4208)是一种嘌呤核苷酸磷酸化酶(PNP)抑制剂,目前正由Biocryst公司开发,旨在治疗痛风,计划作为每日一次的口服长期治疗方案。Ulodesine通过作用于嘌呤代谢途径中黄嘌呤氧化酶上游,来减少血清尿酸(sUA)的产生。其对PNP的半抑制浓度(IC(50))为0.5 nM。目前,BCX-4208还在早期临床试验阶段,用于探索其在银屑病和痛风治疗中的潜在效益。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout. |
别名 | Ulodesine, DADMe-immucillin H, BCX-4208, BCX4208, BCX 4208 |
分子量 | 323.325 |
分子式 | C12H16N4O3 1/2C4H6O4 |
CAS No. | 1246200-39-4 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容